Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease

B. Frederiksen; L. Specht; J. Henrichsen; F.K. Pedersen; J. Pedersen-Bjergaard

Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease

B. Frederiksen, L. Specht, J. Henrichsen, F.K. Pedersen, J. Pedersen-Bjergaard

22 Citations (Scopus)

Abstract

Antibody response to pneumococcal vaccination was studied in 76 patients with Hodgkin's disease (HD) before, during and at different time intervals after cessation of therapy. All patients were in pathological stage I and II following explorative laparatomy with splenectomy. The increase in antibody response was compared to the findings in 12 healthy volunteers with the aim of establishing the optimal time for vaccination. Serum antibodies against 6 of the pneumococcal polysaccharide antigens (types 1, 4, 7F, 14, 18C and 23F) contained in the vaccine were determined by an ELISA. Antibody response to pneumococcal type antigens was similar in healthy adults and in patients with early stage HD before therapy. After treatment, postvaccination antibody response became negligible. Even up to 7 years after cessation of therapy patients were not able to raise a significant antibody response
Udgivelsesdato: 1989/7

Original language	Danish
Journal	European Journal of Haematology
Volume	43
Issue number	1
Pages (from-to)	45-49
Number of pages	4
ISSN	0902-4441
Publication status	Published - 1989

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{562235b04c8811df928f000ea68e967b,

title = "Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease",

abstract = "Antibody response to pneumococcal vaccination was studied in 76 patients with Hodgkin's disease (HD) before, during and at different time intervals after cessation of therapy. All patients were in pathological stage I and II following explorative laparatomy with splenectomy. The increase in antibody response was compared to the findings in 12 healthy volunteers with the aim of establishing the optimal time for vaccination. Serum antibodies against 6 of the pneumococcal polysaccharide antigens (types 1, 4, 7F, 14, 18C and 23F) contained in the vaccine were determined by an ELISA. Antibody response to pneumococcal type antigens was similar in healthy adults and in patients with early stage HD before therapy. After treatment, postvaccination antibody response became negligible. Even up to 7 years after cessation of therapy patients were not able to raise a significant antibody response Udgivelsesdato: 1989/7",

author = "B. Frederiksen and L. Specht and J. Henrichsen and F.K. Pedersen and J. Pedersen-Bjergaard",

note = "DA - 19890928IS - 0902-4441 (Print)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Antibodies, Bacterial)RN - 0 (Antigens, Bacterial)RN - 0 (Bacterial Vaccines)SB - IM",

year = "1989",

language = "Dansk",

volume = "43",

pages = "45--49",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease

AU - Frederiksen, B.

AU - Specht, L.

AU - Henrichsen, J.

AU - Pedersen, F.K.

AU - Pedersen-Bjergaard, J.

N1 - DA - 19890928IS - 0902-4441 (Print)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Antibodies, Bacterial)RN - 0 (Antigens, Bacterial)RN - 0 (Bacterial Vaccines)SB - IM

PY - 1989

Y1 - 1989

N2 - Antibody response to pneumococcal vaccination was studied in 76 patients with Hodgkin's disease (HD) before, during and at different time intervals after cessation of therapy. All patients were in pathological stage I and II following explorative laparatomy with splenectomy. The increase in antibody response was compared to the findings in 12 healthy volunteers with the aim of establishing the optimal time for vaccination. Serum antibodies against 6 of the pneumococcal polysaccharide antigens (types 1, 4, 7F, 14, 18C and 23F) contained in the vaccine were determined by an ELISA. Antibody response to pneumococcal type antigens was similar in healthy adults and in patients with early stage HD before therapy. After treatment, postvaccination antibody response became negligible. Even up to 7 years after cessation of therapy patients were not able to raise a significant antibody response Udgivelsesdato: 1989/7

AB - Antibody response to pneumococcal vaccination was studied in 76 patients with Hodgkin's disease (HD) before, during and at different time intervals after cessation of therapy. All patients were in pathological stage I and II following explorative laparatomy with splenectomy. The increase in antibody response was compared to the findings in 12 healthy volunteers with the aim of establishing the optimal time for vaccination. Serum antibodies against 6 of the pneumococcal polysaccharide antigens (types 1, 4, 7F, 14, 18C and 23F) contained in the vaccine were determined by an ELISA. Antibody response to pneumococcal type antigens was similar in healthy adults and in patients with early stage HD before therapy. After treatment, postvaccination antibody response became negligible. Even up to 7 years after cessation of therapy patients were not able to raise a significant antibody response Udgivelsesdato: 1989/7

M3 - Tidsskriftartikel

SN - 0902-4441

VL - 43

SP - 45

EP - 49

JO - European Journal of Haematology

JF - European Journal of Haematology

IS - 1

ER -